Last reviewed · How we verify

ALKS 9072, Low — Competitive Intelligence Brief

ALKS 9072, Low (ALKS 9072, Low) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Mu opioid receptor partial agonist. Area: Psychiatry / Addiction Medicine.

phase 3 Mu opioid receptor partial agonist Mu opioid receptor (OPRM1) Psychiatry / Addiction Medicine Small molecule Live · refreshed every 30 min

Target snapshot

ALKS 9072, Low (ALKS 9072, Low) — Alkermes, Inc.. ALKS 9072 is a mu opioid receptor partial agonist designed to treat opioid use disorder by reducing cravings and withdrawal symptoms.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ALKS 9072, Low TARGET ALKS 9072, Low Alkermes, Inc. phase 3 Mu opioid receptor partial agonist Mu opioid receptor (OPRM1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Mu opioid receptor partial agonist class)

  1. Alkermes, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ALKS 9072, Low — Competitive Intelligence Brief. https://druglandscape.com/ci/alks-9072-low. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: